

**ESMO Advanced Course on Biomarkers
for Precision Immuno-Oncology
Across Tumours**

PROGRAMME

**ESMO
ADVANCED COURSE**

**ZURICH SWITZERLAND
17-18 NOVEMBER 2023**

Co-Chairs

Samra Turajlic, United Kingdom
Benedikt Westphalen, Germany

ESMO ADVANCED COURSE PROGRAMME BIOMARKERS FOR PRECISION IMMUNO-ONCOLOGY ACROSS TUMOURS

Zurich, Switzerland
17-18 November 2023

CO-CHAIRS Samra Turajlic, United Kingdom
Benedikt Westphalen, Germany

SPEAKERS Roberto Figueroa Salgado, Belgium
Marie-Dominique Galibert, France
Michael Hubank, United Kingdom
Daniel Hübschmann, Germany
Kevin Litchfield, United Kingdom
Miriam Molina, United Kingdom
Natasha Naoun, France
Chantal Pauli, Switzerland
Etienne Rouleau, France
Martin Ziegler, Germany

LEARNING OBJECTIVES

- To understand the concept of biomarker-driven treatment
- To gain insights into the technical and clinical aspects of biomarker testing
- To understand the clinical implications of molecularly guided therapy options
- To integrate this knowledge into clinical decision making

ACCREDITATION

The programme of this event has been accredited with **8 ESMO-MORA category 1 points**.

Recertification is necessary for medical oncologists to remain professionally certified by ESMO. Recertification guarantees that a certified medical oncologist has continued to update his/her knowledge and continues to possess the necessary skills and standards for the practice of medical oncology. For further details please refer to esmo.org.

ACKNOWLEDGEMENTS

This event is supported by an unrestricted educational grant from



ORGANISATION AND CONTACTS

ESMO Head Office
Education Department
Via Ginevra 4
6900 Lugano, Switzerland
Email: courses@esmo.org
www.esmo.org



Friday, 17 November 2023

09:00-09:10 **Welcome and introduction**

10' Welcome and learning objectives introduction
Benedikt Westphalen, DE

09:10-10:45 **Session 1 – Molecular target / Family of targets – DNA damage and mutational signatures** Chairs: Natasha Naoun, FR and Benedikt Westphalen, DE

15' Biology of the target / biomarkers (function and roles in normal and tumour tissue homeostasis)
Etienne Rouleau, FR

5' Q&A

15' Update on the clinical efficacy of approved targeted agents: Formal indications, efficacy and toxicity
Daniel Hübschmann, DE

5' Q&A

20' Testing for the target / biomarker (assays, technicalities and practicalities, challenges for interpretation)
Chantal Pauli, CH

10' Q&A

15' A clinicopathological case presented and discussed by a Molecular Tumour Board
Benedikt Westphalen, DE

10' Q&A

10:45-11:15 **Coffee break**

11:15-12:50 **Session 2 – Molecular target / Family of targets – FGFR** Chairs: Chantal Pauli, CH and Benedikt Westphalen, DE

15' Biology of the target / biomarkers (function and roles in normal and tumour tissue homeostasis)
Martin Ziegler, DE

5' Q&A

15' Update on the clinical efficacy of approved targeted agents: Formal indications, efficacy and toxicity
Natasha Naoun, FR

5' Q&A

20' Testing for the target / biomarker (assays, technicalities and practicalities, challenges for interpretation)
Marie-Dominique Galibert, FR

10' Q&A

15' A clinicopathological case presented and discussed by a Molecular Tumour Board
Benedikt Westphalen, DE

10' Q&A

12:50-13:50 **Lunch**

13:50-15:25 **Session 3 – Molecular target / Family of targets – RAS** Chairs: Marie-Dominique Galibert, FR and Benedikt Westphalen, DE

15' Biology of the target / biomarkers (function and roles in normal and tumour tissue homeostasis)
Miriam Molina, UK

5' Q&A

- 15' Update on the clinical efficacy of approved targeted agents: Formal indications, efficacy and toxicity
Benedikt Westphalen, DE
- 5' Q&A
- 20' Testing for the target / biomarker (assays, technicalities and practicalities, challenges for interpretation)
Michael Hubank, UK
- 10' Q&A
- 15' A clinicopathological case presented and discussed by a Molecular Tumour Board
Daniel Hübschmann, DE
- 10' Q&A
- 19:30 *Networking Dinner***

Saturday, 18 November 2023

- 09:00-12:00 *Session 4 – Molecular target / Family of targets – Immune infiltration and immune checkpoints***
Chairs: Miriam Molina, UK and Daniel Hübschmann, DE
- 25' Biology of the target / biomarkers (function and roles in normal and tumour tissue homeostasis)
Kevin Litchfield, UK
- 10' Q&A
- 25' Update on the clinical efficacy of approved targeted agents: Formal indications, efficacy and toxicity
Author: Samra Turajlic, UK; Presenter: Kevin Litchfield, UK
- 10' Q&A
- 20' Testing for the target / biomarker (assays, technicalities and practicalities, challenges for interpretation)
Roberto Figueroa Salgado, BE
- 10' Q&A
- 10:40-11:10 *Coffee break***
- 15' A clinicopathological case presented and discussed by a Molecular Tumour Board
Roberto Figueroa Salgado, BE
- 10' Q&A
- 15' Value/health economics of testing and targeting (incl. MCBS, ESCAT actionability, RWD)
Michael Hubank, UK
- 10' Q&A
- 12:00-12:15 *Synthesis and wrap-up***
Benedikt Westphalen, DE
- 12:15-13:15 *Lunch***